Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | HGF |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6446H9954N1718O2026S46 |
Molar mass | 145409.30 g·mol−1 |
NY (what is this?) (verify) |
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.[1]
It is a humanized monoclonal antibody that binds to hepatocyte growth factor, thus inhibiting the c-MET receptor signaling cascade.[2]
Ficlatuzumab was developed by AVEO Pharmaceuticals. In May 2012, AVEO released results of a Phase II clinical trial comparing gefitinib alone and in combination with ficlatuzamab in treatment-naive Asian patients with non-small cell lung cancer.[3]
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF |
| ||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) |
| ||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |